Pseudomonas agar base with C-F-C supplement SR103 (PAB-CFC; Oxoid) and pseudomonas isolation agar (PIA; Difco) were prepared as directed by the manufacturers. GH medium was prepared as directed except that cyclohexi-* Corresponding author. mide, an antifungal agent, was omitted. We considered cycloheximide to be unnecessary for the performance of the medium in our application. Pseudomonas selective isolation agar (PSIA) was prepared as follows. A stock solution of 5% (wt/vol) nitrofurantoin, (Sigma Chemical Co., St. Louis, Mo.) was prepared in N,N-dimethylformamide (Fisher Scientific Co., Fair Lawn, N.J.). A stock solution of 0.1% (wt/vol) crystal violet (Sigma) was prepared in deionized water. The stock solutions were stored at room temperature, and the nitrofurantoin solution was protected from exposure to light. The stock solutions were not filter sterilized because they were so highly concentrated that sterile filtration was considered unnecessary. We prepared 1 1 of PSIA by adding 2 ml of crystal violet stock solution to about 990 ml of soybean casein digest agar (SCD; BBL) and then autoclaving and cooling the SCD to -50°C and adding 7 ml of nitrofurantoin stock solution. All media were dispensed in plastic petri dishes (100 by 15 mm) and either used immediately or stored in plastic bags in a refrigerator for up to 1 month.
Pseudomonas selective media are available from Oxoid, Ltd., London, England, and Difco Laboratories, Detroit, Mich. Cephaloridine, Fucidin, and cetrimide are the selective agents in the Oxoid medium. Irgasan is the selective agent in the Difco medium. Hart mide, an antifungal agent, was omitted. We considered cycloheximide to be unnecessary for the performance of the medium in our application. Pseudomonas selective isolation agar (PSIA) was prepared as follows. A stock solution of 5% (wt/vol) nitrofurantoin, (Sigma Chemical Co., St. Louis, Mo.) was prepared in N,N-dimethylformamide (Fisher Scientific Co., Fair Lawn, N.J.). A stock solution of 0.1% (wt/vol) crystal violet (Sigma) was prepared in deionized water. The stock solutions were stored at room temperature, and the nitrofurantoin solution was protected from exposure to light. The stock solutions were not filter sterilized because they were so highly concentrated that sterile filtration was considered unnecessary. We prepared 1 1 of PSIA by adding 2 ml of crystal violet stock solution to about 990 ml of soybean casein digest agar (SCD; BBL) and then autoclaving and cooling the SCD to -50°C and adding 7 ml of nitrofurantoin stock solution. All media were dispensed in plastic petri dishes (100 by 15 mm) and either used immediately or stored in plastic bags in a refrigerator for up to 1 month.
The microorganisms used were 85 Pseudomonas strains representing about 15 species (Table 1) , 63 strains of gramnegative bacteria other than Pseudomonas spp., and 5 Table 3 . PSIA recovered Pseudomonas spp. from 93% of the water samples, with P. stutzeri the most common isolate. GH medium, PAB-CFC, and PIA recovered Pseudomonas spp. from 80, 44, and 34% of the water samples, respectively. PSIA recovered P. aeruginosa from more samples than did the other media. In addition to poor recovery of Pseudomonas spp., PAB-CFC allowed the growth of more nonpseudomonads than did the other media. Overall, field trial results demonstrated the superior performance of PSIA over the other media. Gram-positive bacteria were not recovered. In summary, PSIA performed somewhat better overall than the other media. It was more selective for Pseudomonas spp. than were the commercial media and as selective as GH medium. It was more effective at inhibiting gram-negative nonpseudomonads than was GH medium. Its performance in the field trials was superior to that of the other media, and finally its formulation, consisting of only two readily available ingredients in an SCD base, is inexpensive and easy to prepare. Qualitative evaluation of PSIA will continue as additional isolates of Pseudomonas spp. and other gramnegative bacteria are tested for growth on the medium.
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